

APR 14 2003

Sheet 1 of 9

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: CV01382K	SERIAL NO.: 10/057,629
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT: Harry R. Davis	
		FILING DATE: January 25, 2002	GROUP: 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	FQ	US2003/0013729	01/16/03	Iqbal, et al.	514	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	MS	FR	WO 96/19450	06/27/96	PCT	C07D	205/08	
		FS	WO 97/21676	06/19/97	PCT	C07D	205/09	
		FT	WO 97/41098	11/06/97	PCT	C07D	205/09	
		FU	WO 00/23415	04/27/00	PCT	C07C	69/734	
		FV	WO 00/23416	04/27/00	PCT	C07C	69/734	
		FW	WO 00/23425	04/27/00	PCT	C07D	209/80	
		FX	WO 00/23445	04/27/00	PCT	C07D	471/12	
		FY	WO 00/23451	04/27/00	PCT	C07D	487/14	
		FZ	WO 00/28981	05/25/00	PCT	A61K	31/00	
		GA	WO 00/31548	06/02/00	PCT	G01N	33/68	
		GB	WO 00/32189	06/08/00	PCT	A61K	31/415	
		GC	WO 00/34240	06/15/00	PCT	C07D	205/08	
		GD	WO 00/37057	06/29/00	PCT	A61K	9/48	
		GE	WO 00/37078	06/29/00	PCT	A61K	31/44	X(abs.)
		GF	WO 00/38721	07/06/00	PCT	A61K	45/06	
		GG	WO 00/38722	07/06/00	PCT	A61K	45/06	
		GH	WO 00/38723	07/06/00	PCT	A61K	45/06	
		GI	WO 00/38724	07/06/00	PCT	A61K	45/06	
		GJ	WO 00/38725	07/06/00	PCT	A61K	45/06	
		GK	WO 00/38726	07/06/00	PCT	A61K	45/06	
		GL	WO 00/38727	07/06/00	PCT	A61K	45/06	
		GM	WO 00/38728	07/06/00	PCT	A61K	45/06	
		GN	WO 00/38729	07/06/00	PCT	A61K	45/06	
		GO	WO 00/40247	07/13/00	PCT	C07D	265/26	
		GP	WO 00/45817	08/10/00	PCT	A61K	31/505	
		GQ	WO 00/50392	08/31/00	PCT	C07C	323/52	X(abs.)
		GR	WO 00/53149	09/14/00	PCT	A61K		
		GS	WO 00/53173	09/14/00	PCT	A61K	31/22	
		GT	WO 00/53563	09/14/00	PCT	C07C	59/92	X(abs.)
		GU	WO 00/56403	09/28/00	PCT	A61P	9/10	
		GV	WO 00/57859	10/05/00	PCT	A61K	9/48	
		GW	WO 00/57918	10/05/00	PCT	A61K	47/44	
		GX	WO 00/60107	10/12/00	PCT	C12P	17/10	
		GY	WO 00/63153	10/26/00	PCT	C07C	69/734	
		GZ	WO 00/63161	10/26/00	PCT	C07C	237/30	
		HA	WO 00/63190	10/26/00	PCT	C07D	265/38	
		HB	WO 00/63196	10/26/00	PCT	C07D	277/04	
		HC	WO 00/63209	10/26/00	PCT	C07D	471/04	
	MS	HD	WO 00/63703	10/26/00	PCT	C07D	33/92	

RECEIVED

APR 15 2003
TECH CENTER 1600/2900

APR 14 2003

FORM PTO-1449				U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01382K		SERIAL NO.: 10/057,629	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)						APPLICANT: Harry R. Davis			
						FILING DATE: January 25, 2002		GROUP: 1614	
MS	HE	WO 00/69412	11/23/00	PCT		A61K	9/127		
	HF	WO 00/69445	11/23/00	PCT		A61K	31/785		
	HG	WO 00/72825	12/7/00	PCT		A61K	9/14		
	HH	WO 00/72829	12/07/00	PCT		A61K	9/48		
	HI	WO 00/75103	12/14/00	PCT	abstract only	C07C	235/60	X(abs.)	
	HJ	WO 00/76482	12/21/00	PCT		A61K	9/48		
	HK	WO 00/76488	12/21/00	PCT		A61K	31/00		
	HL	WO 00/78312	12/28/00	PCT		A61K	31/421		
	HM	WO 00/78313	12/28/00	PCT		A61K	31/422		
	HN	WO 01/00579	01/04/01	PCT		C07D	213/65		
	HO	WO 01/00603	01/04/01	PCT		C07D	277/24		
	HP	WO 01/08686	02/08/01	PCT		A61K	31/495		
	HQ	WO 01/12176	02/22/01	PCT		A61K	31/16		
	HR	WO 01/12187	02/22/01	PCT		A61K	31/404		
	HS	WO 01/12612	02/22/01	PCT		C07D	257/04		
	HT	WO 01/14349	03/01/01	PCT	abstract	C07D	277/34	X(abs.)	
	HU	WO 01/14350	03/01/01	PCT	abstract	C07D	277/34	X(abs.)	
	HV	WO 01/14351	03/01/01	PCT	abstract	C07D	277/34	X(abs.)	
	HW	WO 01/15744	03/08/01	PCT		A61K	49/00		
	HX	WO 01/16120	03/08/01	PCT		C07D	263/32		
	HY	WO 01/17994	03/15/01	PCT		C07D	413/12		
	HZ	WO 01/18210	03/15/01	PCT		C12N	15/12		
	IA	WO 01/21181	03/29/01	PCT	abstract	A61K	31/675	X(abs.)	
	IB	WO 01/21259	03/29/01	PCT		A61P			
	IC	WO 01/21578	03/29/01	PCT	abstract	C07C	235/60	X(abs.)	
	ID	WO 01/21647	03/29/01	PCT		C07K	14/00		
	IE	WO 01/22962	04/05/01	PCT		A61K	31/435		
	IF	WO 01/25225	04/12/01	PCT		C07D	317/18		
	IG	WO 01/25226	04/12/01	PCT		C07D	327/04		
	IH	WO 01/30343	05/03/01	PCT		A61K	31/40		
	II	WO 01/32161	05/10/01	PCT		A61K	31/00		
	IJ	WO 01/35970	05/25/01	PCT		A61K	35/76		
	IK	WO 01/40192	06/07/01	PCT	abstract	C07D	217/26	X(abs.)	
	IL	WO 01/45676	06/28/01	PCT		A61K	9/24		
	IM	WO 01/49267	07/12/01	PCT		A61K	9/14		
	IN	WO 01/64221	09/07/01	PCT		A61K	31/52		
	IO	WO 01/76632	10/18/01	PCT		A61K	45/06		
	IP	WO 02/50090	06/27/02	PCT		C07H	15/26		
	IQ	WO 02/058696	08/01/02	PCT		A61K	31/397		
	IR	WO 02/058731	08/01/02	PCT		A61K	45/06		
	IS	WO 02/058732	08/01/02	PCT		A61K	45/06		
	IT	WO 02/058733	08/01/02	PCT		A61K	45/06		
	IU	WO 02/058734	08/01/02	PCT		A61K	45/06		
	IV	WO 02/058685	08/01/02	PCT		A61K	31/00		
	IW	WO 02/064130	08/22/02	PCT		A61K	31/195		
	IX	WO 02/064549	08/22/02	PCT		C07C	275/34		
MS	IY	WO 02/064664	08/22/02	PCT		C08G	77/02		

RECEIVED

APR 15 2003
TECH CENTER 1600/2900

APR 14 2003


Sheet 3 of 9

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01382K		SERIAL NO.: 10/057,629	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: Harry R. Davis			
				FILING DATE: January 25, 2002		GROUP: 1614	
<input checked="" type="checkbox"/>	IZ	WO 02/072104	09/19/02	PCT	A61K	31/54	
<input type="checkbox"/>	JA	WO 02/081454	10/17/02	PCT	C07D	239/36	
<input type="checkbox"/>	JB	WO 02/26729	04/04/02	PCT	C07D	311/66	
<input type="checkbox"/>	JC	WO 02/064094	08/22/02	PCT	A61K		
<input type="checkbox"/>	JD	WO 03/018024	03/06/03	PCT	A61K	31/55	
<input checked="" type="checkbox"/>	JE	WO 03/018059	03/06/03	PCT	A61K	45/06	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
<input checked="" type="checkbox"/>	JF	Vaccaro, W.D. et al., "Sugar-substituted 2-azetidinone cholesterol absorption inhibitors: enhanced potency by modification of the sugar" <i>Bioorganic & Medicinal Chemistry Ltrs.</i> , Oxford, G.B., 8:313-318 (1998)					
<input type="checkbox"/>	JG	Vaccaro, W.D. et al., "Carboxy-substituted 2-azetidinones as cholesterol absorption inhibitors", <i>Bioganic & Medicinal Chem. Ltrs. Oxford, G.B.</i> 8:319-322 (1998)					
<input type="checkbox"/>	JH	H. Davis et al., "Ezetimibe, a Potent Cholesterol Absorption Inhibitor, Inhibits the Development of Atherosclerosis in Apo E Knockout Mice", <i>Arterioscler, Thromb. Vasc. Biol</i> 21:2032-2038, (Dec. 2001)					
<input type="checkbox"/>	JI	Simova, E., "Aldol-type addition of hydrocinnamic acid esters to benzylideneaniline", <i>Chemical Abstracts No. 15</i> , 86 (April 11, 1997)					
<input type="checkbox"/>	JJ	Otto et al., "Stereochemistry of dehydration and halogenation of αR^* and αS^* isomeric 3-(α -hydroxybenzyl)-1,4 diphenyl-2 azetidinones, <i>Chemical Abstracts No. 19</i> , 99 (Nov. 7, 1983)					
<input type="checkbox"/>	JK	T. Durst et al., "Metallation of N-Substituted β -Lactams. A Method of the Introduction of 3-substituents into β -Lactams" <i>Canadian Journal of Chemistry</i> , 50:3196-3201 (1971)					
<input type="checkbox"/>	JL	Nobuki, O. et al., "Stereoselective syntheses of β -lactam derivatives by ultrasound promoted Reformatskii reaction" <i>Chemical Abstracts No. 106</i> , 17 (April 27, 1987)					
<input type="checkbox"/>	JM	M. Hoekman, et al., "Synthesis of Homologues of 4,5-Dihydroxy-and 4-Hydroxy-5-oxohexanoic Acid γ -Lactones", <i>J. Agric. Food Chem.</i> , 30:920-924 (1982)					
<input type="checkbox"/>	JN	H. Otto et al. "Darstellung und Stereochemie von 3-(α -Hydroxybenzyl)-1,4-diphenyl-2-azetidononen", <i>Liebigs Ann. Chem.</i> 1152-1161 (1983)					
<input type="checkbox"/>	JO	G. George et al. "3-(1'-Hydroxyethyl)-2-Azetidinones From 3-Hydroxybutyrates and N-Arylaldimines" <i>Tetrahedron Letters</i> , 26:3903-3906 (1985)					
<input type="checkbox"/>	JP	Hart et al. "An Enantioselective Approach to Carbapenem Antibodies: Formal Synthesis of (+)-Thienamycin", 26 <i>Tetrahedron Letters</i> , 45:5493-5496 (1985)					
<input type="checkbox"/>	JQ	Panfil, I. et al. "Synthesis of β -Lactams from α , β -Unsaturated Sugar δ -Lactones" 24 <i>Heterocycles</i> 6:1609-1617 (1986)					
<input type="checkbox"/>	JR	D. Roger Illingworth, "An Overview of Lipid-Lower Drugs" <i>Drugs</i> 36:63-71 (1988)					
<input type="checkbox"/>	JS	Joseph L. Witztum, M.D., "Current Approaches to Drug Therapy for the Hypercholesterolemic Patient" <i>Circulation</i> 80:1101-1114 (1989)					
<input type="checkbox"/>	JT	B. Ram et al. "Potential Hypolipidemic agents: Part V", 29B Indian J. Chem. 1134-37 (1990)					
<input type="checkbox"/>	JU	Schnitzer-Polokoff, R. et al., "Effects of Acyl-CoA: Cholesterol O-Acyltransferase Inhibition on Cholesterol Absorption and Plasma Lipoprotein Composition in Hamsters" <i>Comp. Biochem. Physiol.</i> 99A:665-670 (1991)					
<input type="checkbox"/>	JV	Horie, M. et al, "Hypolipidemic effects of NB-598 in dogs" <i>Atherosclerosis</i> 88:183-192 (1991)					
<input type="checkbox"/>	JW	Baxter, A., "Squalestatin 1, a Potent Inhibitor of Squalene Synthase, Which Lowers Serum Cholesterol in Vivo", <i>The Journal of Biological Chemistry</i> 267:11705-11708 (1992)					
<input checked="" type="checkbox"/>	JX	Summary Factfile, "Anti-Atherosclerotic Agents" <i>Current Drugs Ltd.</i> (1992)					

RECEIVED

APR 15 2003

TECH CENTER 1600/2000



FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: CV01382K	SERIAL NO.: 10/057,629
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			APPLICANT: Harry R. Davis	
			FILING DATE: January 25, 2002	
			GROUP: 1614	
JY	JY	Harwood H. James, "Pharmacologic consequences of cholesterol absorption inhibition: alteration in cholesterol metabolism and reduction in plasma cholesterol concentration induced by the synthetic saponin β -tigogenin cellobioside (CP-88818; tiqueside) 1" <i>Journal of Lipid Research</i> 34 :377-395 (1993)		
	JZ	Salisbury, B. <i>et al.</i> , "Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461" <i>Atherosclerosis</i> 115 :45-63 (1995)		
	KA	Clader, J. W. <i>et al.</i> , "Substituted (1,2-Diarylethyl)amide Acyl-CoA;Cholesterol Acyltransferase Inhibitors: Effect of Polar Groups in Vitro and in Viro Activity" <i>Journal of Medicinal Chemistry</i> 38 :1600-1607 (1995)		
	KB	Sybertz, E., "Sch 48461, a novel inhibitor of cholesterol absorption" <i>Atherosclerosis</i> pp. 311-315 (1995)		
	KC	Vaccaro, W, <i>et al.</i> , "2-Azetidinone Cholesterol Absorption Inhibitors; Increased Potency by Substitution of the C-4 Phenyl Ring", <i>Bioorg. & Med. Chem.</i> 6 :1429-1437 (1998)		
	KD	G. Wu <i>et al.</i> , "A Novel One-Step Diastereo-and enantioselective formation of trans-azetidinones and its application to the total synthesis of cholesterol absorption inhibitors A.C.S. (4/21/99).		
	KE	B. Staels, "New Roles for PPARS in Cholesterol Homeostasis", <i>Trends in Pharmacological Sciences</i> , 22 :9 p. 444 (Sept. 2001)		
	KF	Abbott <i>et al.</i> , "Tricor® Capsules, Micronized", <i>Physicians Desk Reference</i> , January 8, 2001.		
	KG	M. Feher <i>et al.</i> , 1991, <i>Lipids and Lipid Disorders</i> , p.1-87 (1991).		
	KH	M. Ricote <i>et al.</i> , "New Roles for PPARs in Cholesterol Homeostasis", <i>Trends in Pharmacological Science</i> , Vol. 22 , No. 9 441-443 (2001)		
	KI	C. Dujovne <i>et al.</i> , "Reduction of LDL Cholesterol in Patients with Primary Hypercholesterolemia by SCH 48461: Results of a multicenter Dose-Ranging Study", <i>J. Clin. Pharm.</i> 41 :1 70-78 (Jan. 2001)		
	KJ	W. Oppolzer <i>et al.</i> , "Asymmetric Diels - Alder Reactions, Facile Preparation and Structure of Sulfonamido - Isobornyl Acrylates", <i>Tetrahedron Letters</i> No. 51, 25 :5885-5888 (1984).		
	KK	M. Davidson <i>et al.</i> , "Colesevelam Hydrochloride: a non-absorbed, polymeric cholesterol lowering agent", <i>Expert Opinion Investigating Drugs</i> , 11 :2663-71, (Nov. 2000)		
	KL	M. Davidson <i>et al.</i> , "Colesevelam hydrochloride (cholestagel): a new, potent bileacid sequestrant associated with a low incidence of gastrointestinal effects", <i>159 Arch. Intern. Med.</i> 16 1893-900 (Sept. 1999)		
	KM	I. Wester, "Cholesterol - Lowering effect of plant sterols", <i>Euro. J.Lipid, Sci. Tech.</i> 37-44 (2000).		
	KN	A. Andersson <i>et al.</i> , "Cholesterol -lowering effects of a stanol ester-containing low fat margarine used in conjunction with a strict lipid-lowering diet", <i>1 European Heart. J. Supplements</i> S80 - S90 (1999)		
	KO	H. Gylling <i>et al.</i> , "Reduction of Serum Cholesterol in Postmenopausal Women with Previous Myocardial Infarction and Cholesterol Malabsorption induced by Dietary Sitostanol Ester Margarine, 96 <i>Circulation</i> 12 4226-4231 (Dec. 16, 1997)		
KP	T. Miettinen <i>et al.</i> , "Reduction of Serum Cholesterol with Sitostanol-Ester Margarine in a Mildly Hypercholesterolemic Population", <i>New England Journal of Med.</i> 333 1308-1312 (Nov. 16, 1995)			
KQ	T. Bocan <i>et al.</i> , "The ACAT Inhibitor Avasimibe Reduces Macrophages and Matrix Metalloproteinase Expression in Atherosclerotic Lesions of Hypercholesterolemic Rabbits", <i>Arterioscler Thromb Vasc. Biol.</i> 70-79 (Jan. 2000)			
KR	M. Van Heek <i>et al.</i> , "In Vivo Metabolism - Based Discovery of a Novel Cholesterol Absorption Inhibitor, SCH 58235, in the Rat and Rhesus Monkey through the identification of the active metabolites of SCH48461," <i>283 J. Pharmacol. and Experimental Therapeutics</i> 1 157-163 (1997)			

RECEIVED
APR 13 2003

TECH CENTER 1600/2900

APR 14 2003

Sheet 5 of 9

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01382K	SERIAL NO.: 10/057,629
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: Harry R. Davis	
				FILING DATE: January 25, 2002	
MS	KS	H. Davis <i>et al.</i> , "The Cholesterol Absorption Inhibitor Ezetimibe Inhibits the Development of Atherosclerosis in apo E knockout (-/-) mice fed low fat and western diets," <i>151 Atherosclerosis</i> 1:133 (July 2000)			
	KT	L. Nguyen <i>et al.</i> , "Unexpected Failure of Bile Acid Malabsorption to Stimulate Cholesterol Synthesis in Sitosterolemia with Xanthomatosis", <i>10 Atherosclerosis</i> 2, 289-297 (1990)			
	KU	L. Nguyen <i>et al.</i> , "Regulation of Cholesterol Biosynthesis in Sitosterolemia: effects of lovastatin, Cholestyramine, and dietary sterol restriction," <i>32 J.Lipid Res.</i> 1941-1948 (1991)			
	KV	M. Cobb <i>et al.</i> , "Sitosterolemia: Opposing Effects of cholestyramine and Lovastatin on Plasma Sterol Levels in a Homozygous Girl and Her Heterozygous Father," <i>45 Metabolism</i> 6 673-679 (June 1996)			
	KW	M. Huettinger <i>et al.</i> , "Hypolipidemic Activity of HOE-402 is mediated by Stimulation of the LDL Receptor Pathway", <i>13 Arteriosclerosis and Thrombosis</i> 7 1005-1012 (July 1993).			
	KX	J. Best <i>et al.</i> , "Diabetic Dyslipidaemia", <i>59 Drugs</i> 5 1101-1111 (May 2000)			
	KY	P. Chong, <i>et al.</i> , "Current, New and Future Treatment in Dyslipidaemia and Atherosclerosis", <i>60 Drugs</i> 1 55-93 (July 2000)			
	KZ	M. Brown <i>et al.</i> , "A Receptor - Mediated Pathway for Cholesterol Homeostasis", <i>232 Science</i> 34-47 (April 4, 1986)			
	LA	L. Lipka <i>et al.</i> , "Reduction of LDL-Cholesterol and Elevation of HDL-Cholesterol in Subjects with Primary Hypercholesterolemia by SCH 58235: Pooled Analysis of Two Phase II Studies", <i>JACC</i> 257A (Feb. 2000)			
	LB	Medical Economics, Co., Inc., <i>Physician's Desk Reference</i> , 207-208, 2054 (55 th Ed. 2001)			
	LC	K. Fassbender <i>et al.</i> , "Simvastatin Strongly Reduces Levels of Alzheimer's Disease β -Amyloid Peptides A β 42 and A β 40 in vitro and in vivo", <i>PNAs Early Edition</i> , www.phas.org/cgi/doi/10.1073/phas.081620098 (2001)			
	LD	Andrx Announces Results of Alzheimer's Disease Clinical Study", <i>Andrx Corporate Release</i> (April 11, 2001)			
	LE	Andrx (ADRX): Pos Phase II Results Using Avicor in Alzheimer's: Str Buy; \$130", <i>US Bancorp Piper</i> , April 12, 2001			
	LF	Statins May Protect Against Alzheimer's Disease; much research needed", <i>Geriatrics</i> February 2001			
	LG	Dementia and Statins", <i>The Lancet</i> March 17, 2001			
	LH	Research & Development: Andrx Says Cholesterol Drug May Treat Alzheimers", <i>Reuters</i> April 11, 2001			
	LI	Cholesterol Drugs Ease Alzheimer's Damage; www.usatoday.com April 10, 2001			
	LJ	Lovastatin XL of Use in Alzheimer's? News Edge (May 2, 2001)			
	LK	L. Refolo <i>et al.</i> , "Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model, <i>Neurobiology of Disease</i> 321-331 (2000)			
	LL	D. Kang <i>et al.</i> , "Modulation of Amyloid β -protein Clearance and Alzheimer's Disease Susceptibility by the LDL Receptor - Related Protein Pathway", <i>Journal of Clinical Investigation</i> 106:9, 1159-1166 (Nov. 2000)			
	LM	Y.A. Kesaniemi, "Intestinal Cholesterol Absorption Efficiency in Man is Related to Apoprotein E Phenotype", <i>J. Clin. Invest.</i> 80(2) 578-81 (Aug. 1987)			
	LN	J. Busciglio <i>et al.</i> , "Generation of β -amyloid in the secretory pathway in neuronal and nonneuronal cells", <i>90 Proc. Nat'l. Acad. Sci, USA</i> , 2092-2096 <i>Neurobiology</i> (March 1993)			
	LO	L. Farrer <i>et al.</i> , "Assessment of Genetic Risk for Alzheimer's Disease Among first Degree Relatives", <i>Annals of Neurology</i> 25:5, 485-493 (May 1989)			
MS	LP	A. Goate <i>et al.</i> , "Segregation of a Missense Mutation in the Amyloid Precursor Protein Gene with Familial Alzheimer's Disease", <i>349 Nature</i> No. 6311704-1706 (Feb. 21, 1991)			

RECEIVED

APR 15 2003

TECH CENTER 1A000/2000

APR 14 2003

Sheet 6 of 9

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01382K	SERIAL NO.: 10/057,629
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: Harry R. Davis	
				FILING DATE: January 25, 2002	
18	LQ	D. Mann <i>et al.</i> , "The Pattern of Acquisition of Plaques and Tangle in the Brains of Patients Under 50 years of Age with Down's Syndrome", 89 <i>J. Neuro. Sci.</i> , 169-179 (Feb. 1989)			
	LR	G. McKhann <i>et al.</i> , "Clinical Diagnosis of Alzheimer's Disease", 34 <i>Neurology</i> No. 7, 939-944 (July 1984)			
	LS	D. Selokoe, "Alzheimer's Disease: Genotypes, Pheontype and Treatments", 275 <i>Science</i> , 630-631 (Jan. 31, 1997)			
	LT	C. Van Duijn, <i>et al.</i> , "Familial Aggregation of Alzheimer's Disease and Related Disorders: A collaborative Re-Analysis of Case-Control Studies", 20 <i>Int'l J. Epidemiology</i> No. 2 (Suppl. 2), 513-520 (1991)			
	LU	T Nagahara <i>et al.</i> , "Dibasic (Amidcinoaryl) Propanoic Acid Derivatives as Novel Blood Coagulation Factor Xa Inhibitors", <i>J. Med. Chem</i> 37:1200-1207 (1994)			
	LV	Mellott <i>et al.</i> , "Acceleration of Recombinant Tissue-Type Plasminogen Activator Induced Reperfusion and Prevention of Reocclusion by Recombinant Antistatin, a selective factor Xa Inhibitor, in a Canine Model of Femoral Arterial Thrombosis", <i>Circulation Research</i> , 70:1152-1160 (1992)			
	LW	Sitko <i>et al.</i> , "Conjunctive Enhancement of Enzymatic Thrombolysis and Prevention of Thrombotic Reocclusion With the Selective Factor Xa Inhibitor, Tick Anticoagulant Peptide", <i>Circulation</i> , 85:805-815 (1992)			
	LX	Seymour <i>et al.</i> , 1994, <i>Biochemistry</i> , 33:3949-3959			
	LY	Markwardt, 1994, <i>Thrombosis and Hemostasis</i> , 72:477-479			
	LZ	Mendall <i>et al.</i> , "C-Reactive Protein and its relation to cardiovascular risk factor: A population based cross sectional study", <i>BMJ</i> ; 312:1061-1065 (April 27, 1996)			
	MA	Ridker P. <i>et al.</i> , "Prospective Studies of C-Reactive Protein as a risk factor for cardiovascular disease", 46 <i>J. Investig. Med.</i> ; 8:391-395 (1998)			
	MB	L. Gruberb, 2000, "Inflammatory Markers in Acute Coronary Syndromes: C-reactive protein (CRP) and Chlamydia", <i>American Heart Association Scientific Sessions</i>			
	MC	Waters, D. <i>et al.</i> , "A Controlled Clinical Trial to Assess the Effect of a Calcium Channel Blocker on the Progression of Coronary Atherosclerosis", <i>Circulation</i> ; 82:1940-1953 (1990)			
	MD	Fleckenstein, 1985, <i>Cir. Res.</i> Vol 52 (Suppl. 1) 3-16			
	ME	Fleckenstein, 1983, "Experimental Facts and Therapeutic Prospects", <i>John Wiley, New York</i> , pp. 286-313			
	MF	McCall, D., 1985, "Curr. Pract. Cardiol. Vol. 10, 1-11			
	MG	Remington 1995, "The Science and Practice of Pharmacy, (19 th Ed. 1995) p. 963			
	MH	M. Chistie <i>et al.</i> , "Early - Onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695", 276 <i>J. Biol. Chem.</i> No. 24; 21562-70 (June 15, 2001)			
	MI	C. Janus <i>et al.</i> , "A β Peptide Immunization Reduces Behavioral impairment and Plaques in a Model of Alzheimer's Disease", 408 <i>Nature</i> 21/28; 979-982 (Dec. 2000)			
	MJ	Manual of Laboratory Operations, "Lipid Research Clinics Program Report, Washington, D.C., U.S. Dept. of Health, Education and Welfare Publication; 1:75-628 (1974)			
MK	Steiner, PM <i>et al.</i> , "Standardization of Micromethods for Plasma Cholesterol, Triglyceride and HDL-Cholesterol with the Lipid Clinic's Methodology [abstract], <i>J. Clin. Chem. Clin. Bichem</i> ; 19:850 (1981)				
ML	Steele WG, <i>et al.</i> , "Enzymatic Determinations of Cholesterol in High Density Lipoprotein Fractions Prepared by Precipitation Technique, 22 <i>Clin. Chem.</i> ; 1:98-101 (1976)				
MM	Salen <i>et al.</i> , "Increased Sitosterol Absorption, Decreased Removal and Expanded Body Pools Compensate for Reduced Cholesterol Syntheses in Sitosterolemia with Xanthomatosis", <i>J. Lipid Res.</i> ; 30:1319-1330 (1989)				

RECEIVED

APR 15 2003

TECH CENTER 1000/2300

APR 14 2003

Sheet

7

of

RECEIVED
TECH CENTER 1600129002
APR 15 2003

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01382K	SERIAL NO.: 10/057,629
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: Harry R. Davis	
				FILING DATE: January 25, 2002	
MS	MN	Lutjohann <i>et al.</i> , "Sterol Absorption and Sterol Balance in Phytosterolemia Evaluated by Deuterium-Labeled Sterols: Effect of Sitostanol Treatment", <i>J. Lipid Res.</i> ; 36:8 ; 1763-1773 (1995)			
	MO	Zhang <i>et al.</i> , "Calpain Inhibitor I Increases B- Amyloid Peptide by Inhibiting the Degradation of the Substrate of γ - Secretase" 274 J. Biol. Chem. , 13:8966-8972 (1999)			
	MP	Zhang <i>et al.</i> , "Biochemical Characterization of the γ -Secretase Activity that Produces B-Amyloid Peptides", <i>Biochemistry</i> 40:5049-5055 (2001)			
	MQ	Ida <i>et al.</i> , "Analysis of Heterogeneous BA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay", 271 J. Biol. Chem. ; 37:22908-22914 (1996)			
	MR	Lichtlen, P.R. <i>et al.</i> , 1990, <i>Lancet</i> ; 335:1109-1113			
	MS	Bays <i>et al.</i> , "Effectiveness and Tolerability of Ezetimibe in Patients with Primary Hypercholesterolemia: Pooled Analysis of Two Phase II Studies", <i>Clinical Therapeutics</i> , 23:1209-1230 (2001)			
	MT	E. Leitersdorf <i>et al.</i> , "Cholesterol absorption inhibition: filling an unmet need in lipid-lowering management", <i>European Heart Journal Supplement</i> , 3:E17-E23 (June 2001)			
	MU	Bauer <i>et al.</i> , "Ezetimibe Does not Affect the Pharmacokinetics or Pharmacodynamics of Warfarin", <i>Clinical Pharmacology and Therapeutics</i> , 69:2 p5 (Mar. 6-10, 2001)			
	MV	Keung <i>et al.</i> , "Ezetimibe Does Not Affect the Pharmacokinetics of oral Contraceptives", <i>Clinical Pharmacology and Therapeutics</i> , 69:2 p55 (Mar. 6-10, 2001)			
	MW	Kosoglou <i>et al.</i> , "Pharmacodynamic interaction between fenofibrate and the Cholesterol Absorption Inhibitor Ezetimibe", <i>Workshops Lipid Lowering Drugs 72nd EAS Congress</i> , p. 38 (May 21-23, 2001)			
	MX	T. Kosoglou <i>et al.</i> , "Coadministration of Ezetimibe and Fenofibrate Leads to Favorable Effects On Apo CII and LDL Subfractions", <i>Posters 11. Lipid Lowering Drugs/Novel, 72nd EAS Congress</i> , p. 89 (May 21-23, 2001)			
	MY	L. Reyderman <i>et al.</i> , "Assessment of a Multiple-Dose Drug Interaction Between Ezetimibe and Gemfibrozil", Presented at XIV Int'l Symp. on Drugs Affecting Lipid Metabolism (DALM) N.Y. (Sept. 9-12, 2001)			
	MZ	P. Stavekivich <i>et al.</i> , "Ezetimibe Does Not Affect the Pharmacokinetics and Pharmacodynamics of Glipizide", <i>Clinical Pharmacology & Therapeutics</i> , 69:67 (March 6-10, 2001)			
	NA	Knopp <i>et al.</i> , "Effect of Ezetimibe on Serum Concentrations of Lipid-Soluble Vitamins", <i>Posters 11. Lipid Lowering Drug/Novel 72nd EAS Congress</i> , p. 90 (May 21-23, 2001)			
	NB	Kosoglou <i>et al.</i> , "Pharmacodynamic Interaction Between Fenofibrate and the Cholesterol Absorption Inhibitor Ezetimibe", <i>Workshops Lipid Lowering Drugs, 72nd EAS Congress</i> , p. 38 (March 6-10, 2001)			
	NC	Bays <i>et al.</i> , "Low-Density Lipoprotein Cholesterol Reduction By SCH 58235 (Ezetimibe), A Novel Inhibitor of Intestinal Cholesterol Absorption, in 243 Hypercholesterolemic Subjects: Results of a Dose-Response Study", <i>XII International Symposium on Atherosclerosis, Stockholm, Sweden (June 25-29, 2000)</i>			
ND	Castaner <i>et al.</i> , "Ezetimibe - Hypolipidemic Cholesterol Absorption Inhibitor", <i>Drugs of the Future</i> , 25(7):679-685 (2000)				
NE	Lipka <i>et al.</i> , "Reduction of LDL-Cholesterol and Elevation of HDL-Cholesterol in Subjects with Primary Hypercholesterolemia by Ezetimibe (SCH 58235): Pooled Analysis of Two Phase II Studies", <i>American College of Cardiology Annual Meeting, Anaheim, CA (March 12-15, 2000)</i>				
NF	Van Heek <i>et al.</i> , "Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663", <i>British Journal of Pharmacology</i> , 129:1748-1754 (2000)				

APR 14 2003

Sheet 8

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
CV01382KSERIAL NO.:
10/057,6INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT:
Harry R. DavisFILING DATE:
January 25, 2002GROUP:
1614


(Use several sheets if necessary)

MD	NG	Van Heek <i>et al.</i> , 2000, "The potent cholesterol absorption inhibitor, ezetimibe, is glucuronidated in the intestine, localizes to the intestine, and circulates enterohepatically", <i>XII International Symposium of Atherosclerosis, Stockholm Sweden (June 25-29, 2000)</i>
	NH	Iannucci <i>et al.</i> , "Metabolism of SCH 58235 in the Human, Rat and Dog", <i>47th ASMS Conference on Mass Spectrometry and Allied Topics, Dallas, TX (June 13-17, 1999)</i>
	NI	Reiss <i>et al.</i> , "An Enzymatic Synthesis of Glucuronides of Azetidinone-based Cholesterol Absorption Inhibitors", <i>Bioorganic & Medicinal Chemistry</i> , 7 :2199-2202 (1999)
	NJ	Rosenblum <i>et al.</i> , "Discovery of 1-(4-Fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption", <i>J. Med. Chem.</i> 41 :973-980 (1998)
	NK	Vaccaro <i>et al.</i> , "Sugar-Substituted 2-Azetidinone Cholesterol Absorption Inhibitors: Enhanced Potency by Modification of the Sugar", <i>Bioorganic & Medicinal Chemistry Letters</i> , 8 :313-318 (1998)
	NL	Zaks <i>et al.</i> , "Enzymatic Glucuronidation of a Novel Cholesterol Absorption Inhibitor, SCH 58235", <i>Applied Biochemistry and Biotechnology</i> , 73 :205-214 (1998)
	NM	W. Insull <i>et al.</i> , "Postmenopausal Hypercholesterolemic Women Derive Additive Benefit from Raloxifene and Simvastatin on Lipid Parameters", <i>World Heart Federation 6th International Symposium on Global Risk of Coronary Heart Disease and Stroke - Abstract Book</i> , p. 35 (June 12-15, 2002)
	NN	L. Simons <i>et al.</i> , 2002, "Ezetimibe added to on-going statin therapy for treatment of primary hypercholesterolemia: Efficacy and safety in patients with Type 2 diabetes mellitus", presented at the 38 th Annual Meeting of the EASD, September 1-5, 2002
	NO	C. Allain <i>et al.</i> , 1974, "Enzymatic Determination of Total Serum Cholesterol", <i>Clinical Chemical</i> , 20 :470-475
	NP	R. Mayrhofer <i>et al.</i> , 1980, "Simple-Preparation of 3-Benzylidene-2-azetidinones", <i>Synthesis</i> , 247-248
	NQ	Burrier, R.E. <i>et al.</i> , 1994, "Demonstration of a Direct Effect on Hepatic Acyl CoA:Cholesterol Acyl Transferase (ACAT) Activity By An Orally Administered Enzyme Inhibitor in the Hamster", <i>Biochemical Pharmacology</i> 47 :1545-1551
	NR	Burrier, R.E. <i>et al.</i> , 1994, "The Effect of Acyl CoA:Cholesterol Acyltransferase Inhibitor on the Uptake, Esterification and Secretion of Cholesterol by the Hamster Small Intestine", <i>The Journal of Pharmacology and Experimental Therapeutics</i> 272 :156-163
	NS	E.F. Binder <i>et al.</i> , "Effects of Hormone Replacement Therapy on Serum Lipids in Elderly Women. A Randomized, Placebo-Controlled Trial", <i>134 Ann. Intern. Med.</i> 9 :754-760 (May 1, 2001)
	NT	MR Haymart <i>et al.</i> , "Optimal Management of Dyslipidemia in Women and Men", <i>2 J. Gend. Specif. Med.</i> 6 :37-42 (Nov. - Dec. 1997)
	NU	"Framingham Heart Study Analysis Reveals Some Primary Prevention Subgroups Are Being Overlooked", <i>Heartwire</i> (April 12, 2001)
	NV	"Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), "Third Report of the National Cholesterol Education Program (NCEP)", <i>NIH Publication No. 01-3670</i> (May 2001)
	NW	Van Heek <i>et al.</i> , "Ezetimibe, A Potent Cholesterol Absorption Inhibitor, Normalizes Combined Dyslipidemia in Obese Hyperinsulinemic Hamsters", <i>50 Diabetes</i> 1330-1335 (June 2001)
	NX	"Additional Statins Show Anti-Inflammatory Effect", <i>103 Circulation</i> 1933-35 (April 17, 2001)
	NY	H. Hauser, <i>et al.</i> , "Identification of a Receptor Mediating Absorption of Dietary Cholesterol in the Intestine", <i>Biochemistry</i> 37 :17843-17850, 1998
	NZ	G. Salen, <i>et al.</i> , "Sitosterolemia", <i>Journal of Lipid Research</i> 33 :945-955, 1992
MD	OA	Stedman's Medical Dictionary, 27 th Edition, pg. 1381

RECEIVED
TECH CENTER 1600/2990
APR 15 2003

APR 14 2003

Sheet 9 of 9

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01382K	SERIAL NO.: 10/057,629
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: Harry R. Davis	
				FILING DATE: January 25, 2002	
MS	OB	P.F. Belamarich <i>et al.</i> , "Response to Diet and Cholestyramine in a Patient with Sitosterolemia", <i>Pediatrics</i> , 977-981, (December 1990)			
	OC	G. Salen <i>et al.</i> , "Lethal Atherosclerosis Associated With Abnormal Plasma and Tissue Sterol Composition in Sitosterolemia With Xanthomatosis", <i>Journal of Lipid Research</i> , 1126-1133, (September 1985)			
	OD	G.R. Thompson <i>et al.</i> , "Novel Lipid-Regulating Drugs, Exp. Opin. Invest. Drugs, 9(11):2619-2628, 2000			
MS	OE	International Search Report dated December 18, 2002 corresponding to PCT Application No. PCT/US02/01195			
				DATE CONSIDERED	
				10/18/03	

32205

RECEIVED

APR 15 2003

TECH CENTER 1600/2900